KR102681143B1 - 글루카곤 유사 펩타이드-2(glp-2) 유도체의 지속형 결합체 - Google Patents

글루카곤 유사 펩타이드-2(glp-2) 유도체의 지속형 결합체 Download PDF

Info

Publication number
KR102681143B1
KR102681143B1 KR1020180116327A KR20180116327A KR102681143B1 KR 102681143 B1 KR102681143 B1 KR 102681143B1 KR 1020180116327 A KR1020180116327 A KR 1020180116327A KR 20180116327 A KR20180116327 A KR 20180116327A KR 102681143 B1 KR102681143 B1 KR 102681143B1
Authority
KR
South Korea
Prior art keywords
glp
derivative
conjugate
immunoglobulin
group
Prior art date
Legal status (The legal status is an assumption and is not a legal conclusion. Google has not performed a legal analysis and makes no representation as to the accuracy of the status listed.)
Active
Application number
KR1020180116327A
Other languages
English (en)
Korean (ko)
Other versions
KR20190037181A (ko
Inventor
최재혁
김민영
최인영
정성엽
Original Assignee
한미약품 주식회사
Priority date (The priority date is an assumption and is not a legal conclusion. Google has not performed a legal analysis and makes no representation as to the accuracy of the date listed.)
Filing date
Publication date
Application filed by 한미약품 주식회사 filed Critical 한미약품 주식회사
Publication of KR20190037181A publication Critical patent/KR20190037181A/ko
Priority to KR1020240009740A priority Critical patent/KR102681144B1/ko
Application granted granted Critical
Publication of KR102681143B1 publication Critical patent/KR102681143B1/ko
Active legal-status Critical Current
Anticipated expiration legal-status Critical

Links

Classifications

    • C—CHEMISTRY; METALLURGY
    • C07—ORGANIC CHEMISTRY
    • C07K—PEPTIDES
    • C07K14/00—Peptides having more than 20 amino acids; Gastrins; Somatostatins; Melanotropins; Derivatives thereof
    • C07K14/435—Peptides having more than 20 amino acids; Gastrins; Somatostatins; Melanotropins; Derivatives thereof from animals; from humans
    • C07K14/575—Hormones
    • C07K14/605—Glucagons
    • A—HUMAN NECESSITIES
    • A61—MEDICAL OR VETERINARY SCIENCE; HYGIENE
    • A61K—PREPARATIONS FOR MEDICAL, DENTAL OR TOILETRY PURPOSES
    • A61K38/00—Medicinal preparations containing peptides
    • A—HUMAN NECESSITIES
    • A61—MEDICAL OR VETERINARY SCIENCE; HYGIENE
    • A61K—PREPARATIONS FOR MEDICAL, DENTAL OR TOILETRY PURPOSES
    • A61K47/00—Medicinal preparations characterised by the non-active ingredients used, e.g. carriers or inert additives; Targeting or modifying agents chemically bound to the active ingredient
    • A61K47/50—Medicinal preparations characterised by the non-active ingredients used, e.g. carriers or inert additives; Targeting or modifying agents chemically bound to the active ingredient the non-active ingredient being chemically bound to the active ingredient, e.g. polymer-drug conjugates
    • A61K47/51—Medicinal preparations characterised by the non-active ingredients used, e.g. carriers or inert additives; Targeting or modifying agents chemically bound to the active ingredient the non-active ingredient being chemically bound to the active ingredient, e.g. polymer-drug conjugates the non-active ingredient being a modifying agent
    • A61K47/62—Medicinal preparations characterised by the non-active ingredients used, e.g. carriers or inert additives; Targeting or modifying agents chemically bound to the active ingredient the non-active ingredient being chemically bound to the active ingredient, e.g. polymer-drug conjugates the non-active ingredient being a modifying agent the modifying agent being a protein, peptide or polyamino acid
    • A—HUMAN NECESSITIES
    • A61—MEDICAL OR VETERINARY SCIENCE; HYGIENE
    • A61K—PREPARATIONS FOR MEDICAL, DENTAL OR TOILETRY PURPOSES
    • A61K47/00—Medicinal preparations characterised by the non-active ingredients used, e.g. carriers or inert additives; Targeting or modifying agents chemically bound to the active ingredient
    • A61K47/50—Medicinal preparations characterised by the non-active ingredients used, e.g. carriers or inert additives; Targeting or modifying agents chemically bound to the active ingredient the non-active ingredient being chemically bound to the active ingredient, e.g. polymer-drug conjugates
    • A61K47/51—Medicinal preparations characterised by the non-active ingredients used, e.g. carriers or inert additives; Targeting or modifying agents chemically bound to the active ingredient the non-active ingredient being chemically bound to the active ingredient, e.g. polymer-drug conjugates the non-active ingredient being a modifying agent
    • A61K47/68—Medicinal preparations characterised by the non-active ingredients used, e.g. carriers or inert additives; Targeting or modifying agents chemically bound to the active ingredient the non-active ingredient being chemically bound to the active ingredient, e.g. polymer-drug conjugates the non-active ingredient being a modifying agent the modifying agent being an antibody, an immunoglobulin or a fragment thereof, e.g. an Fc-fragment
    • A—HUMAN NECESSITIES
    • A61—MEDICAL OR VETERINARY SCIENCE; HYGIENE
    • A61P—SPECIFIC THERAPEUTIC ACTIVITY OF CHEMICAL COMPOUNDS OR MEDICINAL PREPARATIONS
    • A61P1/00—Drugs for disorders of the alimentary tract or the digestive system
    • C—CHEMISTRY; METALLURGY
    • C07—ORGANIC CHEMISTRY
    • C07K—PEPTIDES
    • C07K2317/00—Immunoglobulins specific features
    • C07K2317/50—Immunoglobulins specific features characterized by immunoglobulin fragments
    • C07K2317/52—Constant or Fc region; Isotype
    • C—CHEMISTRY; METALLURGY
    • C07—ORGANIC CHEMISTRY
    • C07K—PEPTIDES
    • C07K2317/00—Immunoglobulins specific features
    • C07K2317/50—Immunoglobulins specific features characterized by immunoglobulin fragments
    • C07K2317/52—Constant or Fc region; Isotype
    • C07K2317/53—Hinge
    • C—CHEMISTRY; METALLURGY
    • C07—ORGANIC CHEMISTRY
    • C07K—PEPTIDES
    • C07K2319/00—Fusion polypeptide
    • C07K2319/30—Non-immunoglobulin-derived peptide or protein having an immunoglobulin constant or Fc region, or a fragment thereof, attached thereto

Landscapes

  • Health & Medical Sciences (AREA)
  • Chemical & Material Sciences (AREA)
  • Life Sciences & Earth Sciences (AREA)
  • General Health & Medical Sciences (AREA)
  • Medicinal Chemistry (AREA)
  • Organic Chemistry (AREA)
  • Public Health (AREA)
  • Animal Behavior & Ethology (AREA)
  • Veterinary Medicine (AREA)
  • Pharmacology & Pharmacy (AREA)
  • Bioinformatics & Cheminformatics (AREA)
  • Engineering & Computer Science (AREA)
  • Proteomics, Peptides & Aminoacids (AREA)
  • Epidemiology (AREA)
  • Biophysics (AREA)
  • Zoology (AREA)
  • Genetics & Genomics (AREA)
  • Endocrinology (AREA)
  • Toxicology (AREA)
  • Molecular Biology (AREA)
  • Biochemistry (AREA)
  • Gastroenterology & Hepatology (AREA)
  • Nuclear Medicine, Radiotherapy & Molecular Imaging (AREA)
  • General Chemical & Material Sciences (AREA)
  • Immunology (AREA)
  • Chemical Kinetics & Catalysis (AREA)
  • Peptides Or Proteins (AREA)
  • Medicines That Contain Protein Lipid Enzymes And Other Medicines (AREA)
  • Preparation Of Compounds By Using Micro-Organisms (AREA)
  • Micro-Organisms Or Cultivation Processes Thereof (AREA)
  • Medicinal Preparation (AREA)
  • Medicines Containing Antibodies Or Antigens For Use As Internal Diagnostic Agents (AREA)
  • Pharmaceuticals Containing Other Organic And Inorganic Compounds (AREA)
KR1020180116327A 2017-09-28 2018-09-28 글루카곤 유사 펩타이드-2(glp-2) 유도체의 지속형 결합체 Active KR102681143B1 (ko)

Priority Applications (1)

Application Number Priority Date Filing Date Title
KR1020240009740A KR102681144B1 (ko) 2017-09-28 2024-01-22 글루카곤 유사 펩타이드-2(glp-2) 유도체의 지속형 결합체

Applications Claiming Priority (2)

Application Number Priority Date Filing Date Title
KR1020170126577 2017-09-28
KR20170126577 2017-09-28

Related Child Applications (1)

Application Number Title Priority Date Filing Date
KR1020240009740A Division KR102681144B1 (ko) 2017-09-28 2024-01-22 글루카곤 유사 펩타이드-2(glp-2) 유도체의 지속형 결합체

Publications (2)

Publication Number Publication Date
KR20190037181A KR20190037181A (ko) 2019-04-05
KR102681143B1 true KR102681143B1 (ko) 2024-07-04

Family

ID=65902619

Family Applications (2)

Application Number Title Priority Date Filing Date
KR1020180116327A Active KR102681143B1 (ko) 2017-09-28 2018-09-28 글루카곤 유사 펩타이드-2(glp-2) 유도체의 지속형 결합체
KR1020240009740A Active KR102681144B1 (ko) 2017-09-28 2024-01-22 글루카곤 유사 펩타이드-2(glp-2) 유도체의 지속형 결합체

Family Applications After (1)

Application Number Title Priority Date Filing Date
KR1020240009740A Active KR102681144B1 (ko) 2017-09-28 2024-01-22 글루카곤 유사 펩타이드-2(glp-2) 유도체의 지속형 결합체

Country Status (18)

Country Link
US (3) US11530249B2 (https=)
EP (1) EP3689898B1 (https=)
JP (2) JP7751381B2 (https=)
KR (2) KR102681143B1 (https=)
CN (1) CN111433221B (https=)
AR (1) AR113258A1 (https=)
AU (1) AU2018339210B2 (https=)
BR (1) BR112020006189A2 (https=)
CA (1) CA3084326A1 (https=)
EA (1) EA202090571A1 (https=)
IL (1) IL273528B2 (https=)
MX (1) MX2020004453A (https=)
PH (1) PH12020550105A1 (https=)
SA (1) SA520411644B1 (https=)
SG (1) SG11202002563WA (https=)
TW (2) TWI795443B (https=)
WO (1) WO2019066586A1 (https=)
ZA (1) ZA202001888B (https=)

Families Citing this family (9)

* Cited by examiner, † Cited by third party
Publication number Priority date Publication date Assignee Title
SG11202111311WA (en) 2019-06-14 2021-12-30 Zealand Pharma As Pharmaceutical parenteral composition of dual glp1/2 agonist
JP7846622B2 (ja) * 2019-12-24 2026-04-15 ハンミ ファーマシューティカル カンパニー リミテッド Ｇｌｐ－２又はその結合体を含む、代謝性骨疾患の予防又は治療用薬学的組成物
EP4126004A1 (en) 2020-03-30 2023-02-08 Zealand Pharma A/S Agonist combination
WO2021201654A1 (ko) 2020-04-03 2021-10-07 한미약품 주식회사 Glp-2 유도체 또는 이의 지속형 결합체를 포함하는 방사선요법, 화학요법, 또는 이들의 조합으로 유발된 점막염의 예방 또는 치료용 약학적 조성물
MX2022014671A (es) * 2020-05-22 2023-02-13 Hanmi Pharm Ind Co Ltd Formulacion liquida de conjugado de glp-2 de accion prolongada.
BR112022025141A2 (pt) 2020-06-09 2023-04-25 Vectivbio Ag Fabricação, formulação e dosagem de apraglutida
KR20220092446A (ko) * 2020-12-24 2022-07-01 한미약품 주식회사 단장증후군의 예방 또는 치료를 위한 인슐린 분비 펩타이드 및 glp-2의 병용 요법
JP2025513345A (ja) * 2022-04-18 2025-04-24 ハンミ ファーマシューティカル カンパニー リミテッド 腸疾患の予防又は治療のためのＧＬＰ－２と、インスリン分泌ペプチド、ＴＮＦα抑制剤、又はその両方の併用療法
CN120435309A (zh) 2022-12-23 2025-08-05 韩美药品株式会社 含有glp-2衍生物或其长效缀合物的用于预防或治疗移植物抗宿主病的药物组合物

Family Cites Families (11)

* Cited by examiner, † Cited by third party
Publication number Priority date Publication date Assignee Title
US6096871A (en) 1995-04-14 2000-08-01 Genentech, Inc. Polypeptides altered to contain an epitope from the Fc region of an IgG molecule for increased half-life
JP4046354B2 (ja) 1996-03-18 2008-02-13 ボード オブ リージェンツ，ザ ユニバーシティ オブ テキサス システム 増大した半減期を有する免疫グロブリン様ドメイン
DK1360202T3 (da) * 2001-02-16 2008-09-22 Conjuchem Biotechnologies Inc Langvarigt glucagon-lignende peptid 2 (GLP-2) til behandling af gastrointestinale sygdomme og lidelser
US20090238838A1 (en) * 2003-11-13 2009-09-24 Hanmi Pharm. Ind. Co. Ltd. Insulinotropic peptide conjugate using an immunoglobulin fc
HRP20060362A2 (en) * 2004-04-23 2007-03-31 Conjuchem Biotechnologies Inc. Method for the purification of albumin conjugates
UA95235C2 (en) * 2005-05-04 2011-07-25 Зииланд Фарма А/С Glucagon-like-peptide-2 (glp-2) analogues
JP2008169195A (ja) * 2007-01-05 2008-07-24 Hanmi Pharmaceutical Co Ltd キャリア物質を用いたインスリン分泌ペプチド薬物結合体
US20110171164A1 (en) * 2008-09-19 2011-07-14 Nektar Therapeutics Polymer conjugates of glp-2-like peptides
KR101746686B1 (ko) * 2010-10-26 2017-06-15 한미사이언스 주식회사 면역글로불린 단편을 이용한 글루카곤 유사 펩타이드―２（ｇｌｐ―２）약물 결합체
JP6206972B2 (ja) * 2011-09-12 2017-10-04 アムニクス オペレーティング インコーポレイテッド グルカゴン様ペプチド−２組成物およびその作製法および使用法
KR101895047B1 (ko) * 2011-12-30 2018-09-06 한미사이언스 주식회사 면역글로불린 단편을 이용한 위치 특이적 글루카곤 유사 펩타이드-2 약물 결합체

Also Published As

Publication number Publication date
MX2020004453A (es) 2020-07-24
TW201927806A (zh) 2019-07-16
AU2018339210B2 (en) 2023-02-02
SG11202002563WA (en) 2020-04-29
CA3084326A1 (en) 2019-04-04
SA520411644B1 (ar) 2024-02-25
JP2023138505A (ja) 2023-10-02
AR113258A1 (es) 2020-03-11
CN111433221A (zh) 2020-07-17
JP7751381B2 (ja) 2025-10-08
IL273528B2 (en) 2025-08-01
EP3689898A4 (en) 2021-06-16
EP3689898B1 (en) 2026-04-29
CN111433221B (zh) 2024-12-27
BR112020006189A2 (pt) 2020-10-13
JP2020534840A (ja) 2020-12-03
TWI794897B (zh) 2023-03-01
US20230090790A1 (en) 2023-03-23
IL273528B1 (en) 2025-04-01
US20200262888A1 (en) 2020-08-20
WO2019066586A1 (ko) 2019-04-04
KR20240013836A (ko) 2024-01-30
IL273528A (en) 2020-05-31
TW202142560A (zh) 2021-11-16
TWI795443B (zh) 2023-03-11
KR20190037181A (ko) 2019-04-05
US20220251164A1 (en) 2022-08-11
NZ762962A (en) 2024-07-05
ZA202001888B (en) 2021-05-26
KR102681144B1 (ko) 2024-07-04
EA202090571A1 (ru) 2020-07-30
PH12020550105A1 (en) 2020-12-07
AU2018339210A1 (en) 2020-04-16
EP3689898A1 (en) 2020-08-05
US11530249B2 (en) 2022-12-20

Similar Documents

Publication Publication Date Title
KR102681144B1 (ko) 글루카곤 유사 펩타이드-2(glp-2) 유도체의 지속형 결합체
KR102285378B1 (ko) 글루카곤, glp-1 및 gip 수용체 모두에 활성을 갖는 삼중 활성체의 지속형 결합체
JP6552968B2 (ja) 新規なインスリンアナログ及びその用途
US10188703B2 (en) Method for treating diabetes mellitus by a composition comprising insulin and a GLP-1/glucagon dual agonist
JP6336394B2 (ja) 生理活性ポリペプチド複合体の製造方法
TW201201831A (en) Long-acting interferon beta formulation using immunoglobulin fragment
JP6465817B2 (ja) インスリン位置特異的結合体
US20200254108A1 (en) Long-acting single-chain insulin analog and conjugate thereof
KR102629006B1 (ko) 인슐린 수용체와의 결합력이 감소된 인슐린 아날로그의 결합체 및 이의 용도
KR20160001391A (ko) 신규한 지속형 인슐린 아날로그 결합체 및 이의 용도
EA047924B1 (ru) Конъюгаты производных glp-2 пролонгированного действия
HK40024582A (en) Long-acting conjugate of glucagon-like peptide-2 (glp-2) derivative

Legal Events

Date Code Title Description
PA0109 Patent application

St.27 status event code: A-0-1-A10-A12-nap-PA0109

PG1501 Laying open of application

St.27 status event code: A-1-1-Q10-Q12-nap-PG1501

R17-X000 Change to representative recorded

St.27 status event code: A-3-3-R10-R17-oth-X000

R18-X000 Changes to party contact information recorded

St.27 status event code: A-3-3-R10-R18-oth-X000

A201 Request for examination
PA0201 Request for examination

St.27 status event code: A-1-2-D10-D11-exm-PA0201

R18-X000 Changes to party contact information recorded

St.27 status event code: A-3-3-R10-R18-oth-X000

R18-X000 Changes to party contact information recorded

St.27 status event code: A-3-3-R10-R18-oth-X000

E902 Notification of reason for refusal
PE0902 Notice of grounds for rejection

St.27 status event code: A-1-2-D10-D21-exm-PE0902

A107 Divisional application of patent
E13-X000 Pre-grant limitation requested

St.27 status event code: A-2-3-E10-E13-lim-X000

P11-X000 Amendment of application requested

St.27 status event code: A-2-2-P10-P11-nap-X000

P13-X000 Application amended

St.27 status event code: A-2-2-P10-P13-nap-X000

PA0107 Divisional application

St.27 status event code: A-0-1-A10-A18-div-PA0107

St.27 status event code: A-0-1-A10-A16-div-PA0107

E701 Decision to grant or registration of patent right
PE0701 Decision of registration

St.27 status event code: A-1-2-D10-D22-exm-PE0701

PR0701 Registration of establishment

St.27 status event code: A-2-4-F10-F11-exm-PR0701

PR1002 Payment of registration fee

St.27 status event code: A-2-2-U10-U11-oth-PR1002

Fee payment year number: 1

PG1601 Publication of registration

St.27 status event code: A-4-4-Q10-Q13-nap-PG1601

P14 Amendment of ip right document requested

Free format text: ST27 STATUS EVENT CODE: A-5-5-P10-P14-NAP-X000 (AS PROVIDED BY THE NATIONAL OFFICE)

P14-X000 Amendment of ip right document requested

St.27 status event code: A-5-5-P10-P14-nap-X000